Seroatlas · Human Serome Atlas

IZUMO2

Izumo sperm-egg fusion protein 2

Also known as: C19orf41, IZUM2_HUMAN, MGC33947, SCRL

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UXV1
Gene: IZUMO2
Ensembl: ENSG00000161652
Chromosome: 19
Canonical length: 221 aa
Protein class: Predicted membrane proteins, Transporters
Subcellular location: Acrosome,Mid piece

OverviewNCBI Gene

Predicted to be located in membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

221 residues, UniProt reviewed canonical sequence.

>Q6UXV1|IZUMO2
     1  MPLALTLLLL SGLGAPGGWG CLQCDPLVLE ALGHLRSALI PSRFQLEQLQ ARAGAVLMGM
    61  EGPFFRDYAL NVFVGKVETN QLDLVASFVK NQTQHLMGNS LKDEPLLEEL VTLRANVIKE
   121  FKKVLISYEL KACNPKLCRL LKEEVLDCLH CQRITPKCIH KKYCFVDRQP RVALQYQMDS
   181  KYPRNQALLG ILISVSLAVF VFVVIVVSAC TYRQNRKLLL Q

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IZUMO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 55 nTPM

Expression across tissuesHPA

Tissue

testis: 55 nTPM
midbrain: 0.1 nTPM
prostate: 0.1 nTPM
skin: 0.1 nTPM
thyroid gland: 0.1 nTPM
adipose tissue: 0 nTPM

Single-cell type

early spermatids: 854 nCPM
late spermatids: 417 nCPM
late primary spermatocytes: 358 nCPM
ocular epithelial cells: 7.9 nCPM
undifferentiated spermatogonia: 4.5 nCPM
differentiating spermatogonia: 3.9 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 1.1 nTPM
basal ganglia: 0.9 nTPM
hippocampal formation: 0.8 nTPM
hypothalamus: 0.7 nTPM
thalamus: 0.7 nTPM
cerebellum: 0.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about IZUMO2.

Disease | ImmuneIEDB

Conditions an epitope on IZUMO2 was assayed in.

infertility B cell
male infertility B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.16
gnomAD pLI: 0
gnomAD missense Z: 0.27
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

membrane

Protein domainsUniProt · Pfam · InterPro

Izumo sperm-egg fusion protein
Izumo sperm-egg fusion, Ig domain-associated
Izumo sperm-egg fusion protein 2

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IZUMO2 as an antibody target. Whether an autoantibody or antibody against IZUMO2 could matter depends on whether native IZUMO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IZUMO2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label IZUMO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...